Home LiteratureArticle Details
PMID: 11390574 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S. Review

Genetic subtypes, humoral immunity, and human immunodeficiency virus type 1 vaccine development.

Journal of virology ·Vol. 75 ·No. 13 ·2001-07-00 ·Pages 5721-9

Moore JP, Parren PW, Burton DR

Abstract

暂无摘要

MeSH Terms
AIDS Vaccines/immunology Genotype HIV Antibodies/biosynthesis HIV-1/classification,genetics,immunology Serotyping
Chemicals
AIDS Vaccines HIV Antibodies
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Moore J P
Department of Microbiology and Immunology, Weill Medical College of Cornell University, 1300 York Ave., New York, NY 10021, USA. [email protected]
Parren P W
Burton D R
References (131)
131 references, click to expand
  1. Neutralization of the human immunodeficiency virus type 1 primary isolate JR-FL by human monoclonal antibodies correlates with antibody binding to the oligomeric form of the envelope glycoprotein complex.
    J Virol. 1997 Apr;71(4):2779-85 PMID: 9060632
  2. Comparative functional role of PC7 and furin in the processing of the HIV envelope glycoprotein gp160.
    FEBS Lett. 1997 Mar 17;405(1):68-72 PMID: 9094426
  3. HIV-1 antibody--debris or virion?
    Nat Med. 1997 Apr;3(4):366-7 PMID: 9095159
  4. Localization of human immunodeficiency virus type 1 Gag and Env at the plasma membrane by confocal imaging.
    J Virol. 2000 Sep;74(18):8670-9 PMID: 10954568
  5. The 1918 influenza virus: A killer comes into view.
    Virology. 2000 Sep 1;274(2):241-5 PMID: 10964767
  6. Identification of gp120 regions targeted by a highly potent neutralizing antiserum elicited in a chimpanzee inoculated with a primary human immunodeficiency virus type 1 isolate.
    J Virol. 2000 Oct;74(20):9749-54 PMID: 11000249
  7. Cellular immunity to human immunodeficiency virus type 1 (HIV-1) clades: relevance to HIV-1 vaccine trials in Uganda.
    J Infect Dis. 2000 Nov;182(5):1350-6 PMID: 11023458
  8. Evidence that the transition of HIV-1 gp41 into a six-helix bundle, not the bundle configuration, induces membrane fusion.
    J Cell Biol. 2000 Oct 16;151(2):413-23 PMID: 11038187
  9. HIV-1 membrane fusion: targets of opportunity.
    J Cell Biol. 2000 Oct 16;151(2):F9-14 PMID: 11038194
  10. Unprecedented degree of human immunodeficiency virus type 1 (HIV-1) group M genetic diversity in the Democratic Republic of Congo suggests that the HIV-1 pandemic originated in Central Africa.
    J Virol. 2000 Nov;74(22):10498-507 PMID: 11044094
  11. Immunoreactivity of intact virions of human immunodeficiency virus type 1 (HIV-1) reveals the existence of fewer HIV-1 immunotypes than genotypes.
    J Virol. 2000 Nov;74(22):10670-80 PMID: 11044111
  12. Characterization of a virtually full-length human immunodeficiency virus type 1 genome of a prevalent intersubtype (C/B') recombinant strain in China.
    J Virol. 2000 Dec;74(23):11367-76 PMID: 11070037
  13. Inter- and intraclade neutralization of human immunodeficiency virus type 1: genetic clades do not correspond to neutralization serotypes but partially correspond to gp120 antigenic serotypes.
    J Virol. 1996 Jan;70(1):427-44 PMID: 8523556
  14. Quantitative analysis of serum neutralization of human immunodeficiency virus type 1 from subtypes A, B, C, D, E, F, and I: lack of direct correlation between neutralization serotypes and genetic subtypes and evidence for prevalent serum-dependent infectivity enhancement.
    J Virol. 1996 Jan;70(1):445-58 PMID: 8523557
  15. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1.
    J Virol. 1996 Feb;70(2):1100-8 PMID: 8551569
  16. Differential role of V3-specific antibodies in neutralization assays involving primary and laboratory-adapted isolates of HIV type 1.
    AIDS Res Hum Retroviruses. 1995 Nov;11(11):1379-91 PMID: 8573396
  17. Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group.
    J Infect Dis. 1996 Feb;173(2):340-8 PMID: 8568294
  18. Antibody cross-competition analysis of the human immunodeficiency virus type 1 gp120 exterior envelope glycoprotein.
    J Virol. 1996 Mar;70(3):1863-72 PMID: 8627711
  19. Quantitative model of antibody- and soluble CD4-mediated neutralization of primary isolates and T-cell line-adapted strains of human immunodeficiency virus type 1.
    J Virol. 1996 Jun;70(6):3668-77 PMID: 8648701
  20. Diverse HIV-1 genetic subtypes in UK.
    Lancet. 1996 May 25;347(9013):1487 PMID: 8676656
  21. Evidence for limited within-person evolution of the V3 domain of the HIV-1 envelope in the amsterdam population.
    AIDS. 1996 Jan;10(1):31-7 PMID: 8924249
  22. Multivariate analysis of human immunodeficiency virus type 1 neutralization data.
    J Virol. 1996 Sep;70(9):6235-43 PMID: 8709250
  23. Restricted antigenic variability of the epitope recognized by the neutralizing gp41 antibody 2F5.
    AIDS. 1996 Jun;10(6):587-93 PMID: 8780812
  24. Human antibody responses to HIV type 1 glycoprotein 41 cloned in phage display libraries suggest three major epitopes are recognized and give evidence for conserved antibody motifs in antigen binding.
    AIDS Res Hum Retroviruses. 1996 Jul 1;12(10):911-24 PMID: 8798976
  25. Immunogenic presentation of a conserved gp41 epitope of human immunodeficiency virus type 1 on recombinant surface antigen of hepatitis B virus.
    J Gen Virol. 1996 Sep;77 ( Pt 9):2001-8 PMID: 8810996
  26. Genetic analysis reveals epidemiologic patterns in the spread of human immunodeficiency virus.
    Am J Epidemiol. 2000 Nov 1;152(9):814-22 PMID: 11085392
  27. Understanding the genetic diversity of HIV-1.
    AIDS. 2000;14 Suppl 3:S31-44 PMID: 11086847
  28. Genetic diversity of HIV-1: the moving target.
    AIDS. 2000;14 Suppl 3:S129-40 PMID: 11086856
  29. Antigenicity and immunogenicity of the HIV-1 gp41 epitope ELDKWA inserted into permissive sites of the MalE protein.
    Vaccine. 2000 Nov 22;19(7-8):684-93 PMID: 11115689
  30. Antibody binding and neutralization of primary and T-cell line-adapted isolates of human immunodeficiency virus type 1.
    J Virol. 2001 Mar;75(6):2741-52 PMID: 11222697
  31. The antiviral activity of antibodies in vitro and in vivo.
    Adv Immunol. 2001;77:195-262 PMID: 11293117
  32. Structural identification of the antibody-binding sites of Hong Kong influenza haemagglutinin and their involvement in antigenic variation.
    Nature. 1981 Jan 29;289(5796):373-8 PMID: 6162101
  33. Comparative analyses of the specificities of anti-influenza hemagglutinin antibodies in human sera.
    J Virol. 1986 Jan;57(1):124-8 PMID: 3941436
  34. The antigenicity and evolution of influenza H1 haemagglutinin, from 1950-1957 and 1977-1983: two pathways from one gene.
    Virology. 1986 Jan 30;148(2):275-87 PMID: 3942036
  35. Fine structure of human immunodeficiency virus (HIV) and immunolocalization of structural proteins.
    Virology. 1987 Jan;156(1):171-6 PMID: 3643678
  36. Endoproteolytic cleavage of gp160 is required for the activation of human immunodeficiency virus.
    Cell. 1988 Apr 8;53(1):55-67 PMID: 2450679
  37. Changes in the transmembrane region of the human immunodeficiency virus type 1 gp41 envelope glycoprotein affect membrane fusion.
    J Virol. 1990 Dec;64(12):6314-8 PMID: 2243396
  38. Identification of the envelope V3 loop as the primary determinant of cell tropism in HIV-1.
    Science. 1991 Jul 5;253(5015):71-4 PMID: 1905842
  39. Conformational changes induced in the human immunodeficiency virus envelope glycoprotein by soluble CD4 binding.
    J Exp Med. 1991 Aug 1;174(2):407-15 PMID: 1713252
  40. Influenza virus hemagglutinin with multibasic cleavage site is activated by furin, a subtilisin-like endoprotease.
    EMBO J. 1992 Jul;11(7):2407-14 PMID: 1628614
  41. Factors underlying spontaneous inactivation and susceptibility to neutralization of human immunodeficiency virus.
    Virology. 1992 Aug;189(2):695-714 PMID: 1386485
  42. Effects of amino acid changes in the extracellular domain of the human immunodeficiency virus type 1 gp41 envelope glycoprotein.
    J Virol. 1993 May;67(5):2747-55 PMID: 8474172
  43. Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding.
    J Virol. 1993 Jul;67(7):3978-88 PMID: 7685405
  44. Immunochemical analysis of the gp120 surface glycoprotein of human immunodeficiency virus type 1: probing the structure of the C4 and V4 domains and the interaction of the C4 domain with the V3 loop.
    J Virol. 1993 Aug;67(8):4785-96 PMID: 7687303
  45. Adaptation to persistent growth in the H9 cell line renders a primary isolate of human immunodeficiency virus type 1 sensitive to neutralization by vaccine sera.
    J Virol. 1995 Jan;69(1):39-48 PMID: 7983734
  46. Epitope exposure on functional, oligomeric HIV-1 gp41 molecules.
    Virology. 1995 Jan 10;206(1):713-7 PMID: 7530400
  47. Recombination in HIV-1.
    Nature. 1995 Mar 9;374(6518):124-6 PMID: 7877682
  48. Antigenic variation and serotyping of HIV type 1 from four World Health Organization-sponsored HIV vaccine sites. WHO Network for HIV Isolation and Characterization.
    AIDS Res Hum Retroviruses. 1994 Nov;10(11):1369-77 PMID: 7888190
  49. A broadly neutralizing human monoclonal antibody against gp41 of human immunodeficiency virus type 1.
    AIDS Res Hum Retroviruses. 1994 Dec;10(12):1651-8 PMID: 7888224
  50. Dual infection with human immunodeficiency virus type 1 of distinct envelope subtypes in humans.
    J Infect Dis. 1995 Apr;171(4):805-10 PMID: 7706806
  51. Serotyping of primary human immunodeficiency virus type 1 isolates from diverse geographic locations by flow cytometry.
    J Virol. 1995 Jun;69(6):3807-15 PMID: 7745728
  52. Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer.
    J Exp Med. 1995 Jul 1;182(1):185-96 PMID: 7540648
  53. Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG.
    J Virol. 1995 Nov;69(11):6609-17 PMID: 7474069
  54. Mucosal model of immunization against human immunodeficiency virus type 1 with a chimeric influenza virus.
    J Virol. 1995 Nov;69(11):6678-86 PMID: 7474077
  55. Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection.
    J Virol. 1999 Dec;73(12):10489-502 PMID: 10559367
  56. Simplified strategy for detection of recombinant human immunodeficiency virus type 1 group M isolates by gag/env heteroduplex mobility assay. Study Group on Heterogeneity of HIV Epidemics in African Cities.
    J Virol. 2000 Jan;74(1):363-70 PMID: 10590125
  57. Influenza A virus recycling revisited.
    Bull World Health Organ. 1999;77(10):820-8 PMID: 10593030
  58. A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure.
    J Virol. 2000 Jan;74(2):627-43 PMID: 10623724
  59. Intersubtype recombinant HIV type 1 involving HIV-MAL-like and subtype H-like sequence in four Norwegian cases.
    AIDS Res Hum Retroviruses. 2000 Jan 1;16(1):49-58 PMID: 10628816
  60. Oligomeric modeling and electrostatic analysis of the gp120 envelope glycoprotein of human immunodeficiency virus.
    J Virol. 2000 Feb;74(4):1961-72 PMID: 10644369
  61. Vaccines and the induction of functional antibodies: time to look beyond the molecules of natural infection?
    Nat Med. 2000 Feb;6(2):123-5 PMID: 10655088
  62. Effects of oligomerization on the epitopes of the human immunodeficiency virus type 1 envelope glycoproteins.
    Virology. 2000 Feb 15;267(2):220-8 PMID: 10662617
  63. HIV-1 diversity in France, 1996-1998. The AC 11 laboratory network.
    AIDS. 2000 Feb 18;14(3):289-96 PMID: 10716505
  64. A global neutralization resistance phenotype of human immunodeficiency virus type 1 is determined by distinct mechanisms mediating enhanced infectivity and conformational change of the envelope complex.
    J Virol. 2000 May;74(9):4183-91 PMID: 10756031
  65. HIV-1 nomenclature proposal.
    Science. 2000 Apr 7;288(5463):55-6 PMID: 10766634
  66. An improved algorithm for determining HIV type 1 subtypes in a primary laboratory in Uganda.
    AIDS Res Hum Retroviruses. 2000 May 1;16(7):621-5 PMID: 10791872
  67. Determining neutralization serotypes of HIV type 1 by neural networks.
    AIDS Res Hum Retroviruses. 1996 Dec 10;12(18):1667-9 PMID: 8959241
  68. Characterization of neutralizing monoclonal antibodies to linear and conformation-dependent epitopes within the first and second variable domains of human immunodeficiency virus type 1 gp120.
    J Virol. 1993 Aug;67(8):4932-44 PMID: 7687306
  69. Probing the structure of the V2 domain of human immunodeficiency virus type 1 surface glycoprotein gp120 with a panel of eight monoclonal antibodies: human immune response to the V1 and V2 domains.
    J Virol. 1993 Oct;67(10):6136-51 PMID: 7690418
  70. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1.
    J Virol. 1993 Nov;67(11):6642-7 PMID: 7692082
  71. Conformational changes induced in the envelope glycoproteins of the human and simian immunodeficiency viruses by soluble receptor binding.
    J Virol. 1993 Dec;67(12):7383-93 PMID: 7693970
  72. Probing the structure of the human immunodeficiency virus surface glycoprotein gp120 with a panel of monoclonal antibodies.
    J Virol. 1994 Jan;68(1):469-84 PMID: 7504741
  73. Truncation of the cytoplasmic domain of the simian immunodeficiency virus envelope glycoprotein alters the conformation of the external domain.
    J Virol. 1994 Feb;68(2):585-91 PMID: 8289362
  74. Neutralization of divergent human immunodeficiency virus type 1 variants and primary isolates by IAM-41-2F5, an anti-gp41 human monoclonal antibody.
    Proc Natl Acad Sci U S A. 1994 Apr 12;91(8):3348-52 PMID: 7512731
  75. Amino acid substitutions in the human immunodeficiency virus type 1 gp120 V3 loop that change viral tropism also alter physical and functional properties of the virion envelope.
    J Virol. 1994 Jul;68(7):4409-19 PMID: 7515973
  76. A novel, glycan-dependent epitope in the V2 domain of human immunodeficiency virus type 1 gp120 is recognized by a highly potent, neutralizing chimpanzee monoclonal antibody.
    J Virol. 1994 Jul;68(7):4636-42 PMID: 7515975
  77. Effects of cytoplasmic domain length on cell surface expression and syncytium-forming capacity of the simian immunodeficiency virus envelope glycoprotein.
    Virology. 1994 Aug 15;203(1):8-19 PMID: 8030287
  78. Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1.
    J Virol. 1994 Aug;68(8):4821-8 PMID: 7518527
  79. Cryptic nature of envelope V3 region epitopes protects primary monocytotropic human immunodeficiency virus type 1 from antibody neutralization.
    J Virol. 1994 Sep;68(9):6006-13 PMID: 8057475
  80. Generation of human monoclonal antibodies against HIV-1 proteins; electrofusion and Epstein-Barr virus transformation for peripheral blood lymphocyte immortalization.
    AIDS Res Hum Retroviruses. 1994 Apr;10(4):359-69 PMID: 7520721
  81. Neutralization of primary human immunodeficiency virus type 1 isolates by the broadly reactive anti-V3 monoclonal antibody, 447-52D.
    J Virol. 1994 Nov;68(11):6994-7000 PMID: 7933081
  82. Human anti-V2 monoclonal antibody that neutralizes primary but not laboratory isolates of human immunodeficiency virus type 1.
    J Virol. 1994 Dec;68(12):8312-20 PMID: 7525987
  83. Exploration of antigenic variation in gp120 from clades A through F of human immunodeficiency virus type 1 by using monoclonal antibodies.
    J Virol. 1994 Dec;68(12):8350-64 PMID: 7525988
  84. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody.
    Science. 1994 Nov 11;266(5187):1024-7 PMID: 7973652
  85. Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120.
    J Virol. 1995 Jan;69(1):101-9 PMID: 7527081
  86. Identification and characterization of monoclonal antibodies specific for polymorphic antigenic determinants within the V2 region of the human immunodeficiency virus type 1 envelope glycoprotein.
    J Virol. 1995 Jan;69(1):222-30 PMID: 7527084
  87. HIV-1 neutralization: the consequences of viral adaptation to growth on transformed T cells.
    AIDS. 1995;9 Suppl A:S117-36 PMID: 8819579
  88. Human immunodeficiency virus type 1 neutralizing antibody serotyping using serum pools and an infectivity reduction assay.
    AIDS Res Hum Retroviruses. 1996 Sep 20;12(14):1319-28 PMID: 8891111
  89. Neutralization serotypes of human immunodeficiency virus type 1 field isolates are not predicted by genetic subtype. The WHO Network for HIV Isolation and Characterization.
    J Virol. 1996 Nov;70(11):7827-32 PMID: 8892904
  90. Core structure of gp41 from the HIV envelope glycoprotein.
    Cell. 1997 Apr 18;89(2):263-73 PMID: 9108481
  91. Mapping the protein surface of human immunodeficiency virus type 1 gp120 using human monoclonal antibodies from phage display libraries.
    J Mol Biol. 1997 Apr 4;267(3):684-95 PMID: 9126846
  92. Evaluation of monoclonal antibodies to human immunodeficiency virus type 1 primary isolates by neutralization assays: performance criteria for selecting candidate antibodies for clinical trials. AIDS Clinical Trials Group Antibody Selection Working Group.
    J Infect Dis. 1997 May;175(5):1056-62 PMID: 9129066
  93. Recombinant human monoclonal antibody IgG1b12 neutralizes diverse human immunodeficiency virus type 1 primary isolates.
    AIDS Res Hum Retroviruses. 1997 May 1;13(7):575-82 PMID: 9135875
  94. Antibodies with specificity to native gp120 and neutralization activity against primary human immunodeficiency virus type 1 isolates elicited by immunization with oligomeric gp160.
    J Virol. 1997 Jun;71(6):4319-30 PMID: 9151820
  95. Atomic structure of the ectodomain from HIV-1 gp41.
    Nature. 1997 May 22;387(6631):426-30 PMID: 9163431
  96. Dimeric association and segmental variability in the structure of human CD4.
    Nature. 1997 May 29;387(6632):527-30 PMID: 9168119
  97. Genetic and immunologic characterization of viruses infecting MN-rgp120-vaccinated volunteers.
    J Infect Dis. 1997 Aug;176(2):384-97 PMID: 9237703
  98. A vaccine for HIV type 1: the antibody perspective.
    Proc Natl Acad Sci U S A. 1997 Sep 16;94(19):10018-23 PMID: 9294155
  99. Analysis of the interaction of the human immunodeficiency virus type 1 gp120 envelope glycoprotein with the gp41 transmembrane glycoprotein.
    J Virol. 1997 Dec;71(12):9722-31 PMID: 9371638
  100. HIV-1 subtypes: implications for epidemiology, pathogenicity, vaccines and diagnostics. Workshop Report from the European Commission (DG XII, INCO-DC) and the Joint United Nations Programme on HIV/AIDS.
    AIDS. 1997 Dec;11(15):17-36 PMID: 9412719
  101. Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines.
    J Virol. 1998 Feb;72(2):1552-76 PMID: 9445059
  102. The antibody response in HIV-1 infection.
    AIDS. 1997;11 Suppl A:S87-98 PMID: 9451972
  103. Neutralization of primary and T-cell line adapted isolates of human immunodeficiency virus type 1: role of V3-specific antibodies.
    J Gen Virol. 1998 Jan;79 ( Pt 1):77-82 PMID: 9460926
  104. Analysis of intercurrent human immunodeficiency virus type 1 infections in phase I and II trials of candidate AIDS vaccines. AIDS Vaccine Evaluation Group, and the Correlates of HIV Immune Protection Group.
    J Infect Dis. 1998 Feb;177(2):310-9 PMID: 9466516
  105. Serotyping of HIV type 1 infections: definition, relationship to viral genetic subtypes, and assay evaluation. UNAIDS Network for HIV-1 Isolation and Characterization.
    AIDS Res Hum Retroviruses. 1998 Mar 1;14(4):311-8 PMID: 9519892
  106. Neutralization of human immunodeficiency virus type 1 by antibody to gp120 is determined primarily by occupancy of sites on the virion irrespective of epitope specificity.
    J Virol. 1998 May;72(5):3512-9 PMID: 9557629
  107. The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens.
    Science. 1998 Jun 19;280(5371):1884-8 PMID: 9632381
  108. A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding.
    Science. 1998 Jun 19;280(5371):1949-53 PMID: 9632396
  109. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody.
    Nature. 1998 Jun 18;393(6686):648-59 PMID: 9641677
  110. The antigenic structure of the HIV gp120 envelope glycoprotein.
    Nature. 1998 Jun 18;393(6686):705-11 PMID: 9641684
  111. Lack of correlation between V3-loop peptide enzyme immunoassay serologic subtyping and genetic sequencing.
    AIDS. 1998 Aug 20;12(12):1405-12 PMID: 9727560
  112. Development of bivalent rgp120 vaccines to prevent HIV type 1 infection.
    AIDS Res Hum Retroviruses. 1998 Oct;14 Suppl 3:S277-89 PMID: 9814956
  113. Antibody neutralization-resistant primary isolates of human immunodeficiency virus type 1.
    J Virol. 1998 Dec;72(12):10270-4 PMID: 9811774
  114. Characterization of sera from subjects infected with HIV-1 subtypes B and E in Thailand by antibody binding and neutralization.
    J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Dec 1;19(4):315-20 PMID: 9833739
  115. Distinct recognition of non-clade B human immunodeficiency virus type 1 epitopes by cytotoxic T lymphocytes generated from donors infected in Africa.
    J Virol. 1999 Feb;73(2):1708-14 PMID: 9882385
  116. Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys.
    Nat Med. 1999 Feb;5(2):204-10 PMID: 9930869
  117. Subtype G and multiple forms of A/G intersubtype recombinant human immunodeficiency virus type 1 in Nigeria.
    Virology. 1999 Feb 15;254(2):226-34 PMID: 9986789
  118. Antibody neutralization of HIV-1 and the potential for vaccine design.
    Immunol Lett. 1999 Mar;66(1-3):143-9 PMID: 10203047
  119. Discrimination of subtype B and non-subtype B strains of human immunodeficiency virus type 1 by serotyping: correlation with genotyping.
    J Clin Microbiol. 1999 May;37(5):1356-60 PMID: 10203486
  120. Cross-subtype neutralizing antibodies induced in baboons by a subtype E gp120 immunogen based on an R5 primary human immunodeficiency virus type 1 envelope.
    J Virol. 1999 Jun;73(6):4640-50 PMID: 10233923
  121. MN and IIIB recombinant glycoprotein 120 vaccine-induced binding antibodies to native envelope glycoprotein of human immunodeficiency virus type 1 primary isolates. National Institute of Allergy and Infectious Disease Aids Vaccine Evaluation Group.
    AIDS Res Hum Retroviruses. 1999 Jul 1;15(10):921-30 PMID: 10408729
  122. Epitope insertion into variable loops of HIV-1 gp120 as a potential means to improve immunogenicity of viral envelope protein.
    Vaccine. 1999 Jul 16;17(22):2862-72 PMID: 10438057
  123. T lymphocyte responses in HIV-1 infection: implications for vaccine development.
    Curr Opin Immunol. 1999 Aug;11(4):451-9 PMID: 10448136
  124. Analysis of the critical domain in the V3 loop of human immunodeficiency virus type 1 gp120 involved in CCR5 utilization.
    J Virol. 1999 Oct;73(10):8216-26 PMID: 10482572
  125. Independent introduction of transmissible F/D recombinant HIV-1 from Africa into Belgium and The Netherlands.
    Virology. 2000 May 10;270(2):267-77 PMID: 10792985
  126. Differential narrow focusing of immunodominant human immunodeficiency virus gag-specific cytotoxic T-lymphocyte responses in infected African and caucasoid adults and children.
    J Virol. 2000 Jun;74(12):5679-90 PMID: 10823876
  127. Timing the ancestor of the HIV-1 pandemic strains.
    Science. 2000 Jun 9;288(5472):1789-96 PMID: 10846155
  128. The role of nonhuman primates in the development of an AIDS vaccine.
    AIDS. 1999;13 Suppl A:S113-20 PMID: 10885770
  129. The neutralizing antibody response to HIV-1: viral evasion and escape from humoral immunity.
    AIDS. 1999;13 Suppl A:S137-62 PMID: 10885772
  130. Conserved and exposed epitopes on intact, native, primary human immunodeficiency virus type 1 virions of group M.
    J Virol. 2000 Aug;74(15):7096-107 PMID: 10888650
  131. Identification and characterization of sera from HIV-infected individuals with broad cross-neutralizing activity against group M (env clade A-H) and group O primary HIV-1 isolates.
    J Med Virol. 2000 Sep;62(1):14-24 PMID: 10935983
Article Info
Journal
Journal of virology
Abbr.
J Virol
ISSN
0022-538X
DOI
10.1128/JVI.75.13.5721-5729.2001
Email
[email protected]
Published
2001-07-00
Pages
5721-9
Language
English
Region
United States
NLM ID
0113724
PMCID
PMC114288
Subset
IM
Grants
NHLBI NIH HHS · HL59727 · United States
NIAID NIH HHS · AI40377 · United States
NIAID NIH HHS · R01 AI036082 · United States
NIAID NIH HHS · R37 AI036082 · United States
NIAID NIH HHS · AI45463 · United States
NIAID NIH HHS · R37 AI033292 · United States
NIAID NIH HHS · R01 AI033292 · United States
NIAID NIH HHS · R01 AI045463 · United States
NIAID NIH HHS · AI36082 · United States
NIAID NIH HHS · AI44293 · United States
NIAID NIH HHS · AI33292 · United States
External Links
PubMed source DOI: 10.1128/JVI.75.13.5721-5729.2001 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2